Eugene Boland
2026 may remain a turbulent period for cell and gene therapy companies approaching BLA submissions, particularly those developing treatments for rare and orphan diseases. Small businesses—often considered the innovation engine of the U.S. biotech ecosystem—have traditionally focused on these areas because clinical trials typically require smaller patient populations while addressing significant unmet medical needs. However, recent strategic shifts in regulatory expectations have made approvals more challenging.
Changes to primary endpoints and analytical approaches during trials can place smaller companies at greater risk of failure due to their limited financial and operational resources. Although new guidance documents suggest the possibility of renewed regulatory flexibility, their impact remains uncertain. Leadership transitions within the regulatory landscape may further contribute to instability as the industry continues to adapt.
